Scientists have made significant progress in developing a vaccine against enterotoxigenic Escherichia coli (ETEC), a bacterium responsible for millions of diarrheal illnesses each year.
After decades of research, the technology has been licensed to a French vaccine manufacturer for further development.
ETEC is one of the most common bacterial causes of severe diarrhea worldwide, disproportionately affecting children in low- and middle-income countries.
Despite years of research, there is currently no broadly effective vaccine to prevent the infection.
The researchers focused on a toxin produced by ETEC that has long been considered one of the biggest obstacles to vaccine development.
Experts say the findings represent a promising step towards creating an effective vaccine against ETEC.
However, more work is needed to translate these findings into an actual vaccine.
The researchers hope that if the vaccine eventually reaches patients, it could help protect children against some of the most severe forms of diarrheal disease caused by ETEC.
In the meantime, experts recommend taking steps to reduce the risk of diarrheal illnesses, including avoiding high-risk foods and practicing good hand hygiene.
Travelers can also consult their physician before traveling internationally to ensure they are protected against other diseases, such as typhoid fever.
While the technology is promising, it is still in development and has not yet been tested as an approved vaccine among the public.
Additional laboratory studies, clinical trials, and regulatory review will be required before the vaccine becomes available.
